AMF Tjanstepension 13F: Cuts AbbVie (ABBV) Stake by $1.8M

AMF Tjanstepension reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 21.9% during the quarter, according to a Form 13F filing with the SEC on October 22, 2026. The institutional investor sold 6,790 shares, leaving it with 24,119 shares worth about $6.31 million.

ABBV AbbVie Inc.

$284.80 ▲ +27.91% year to date

1M 3M YTD

Daily close · Oct 21, 2026

What Changed in AMF Tjanstepension's AbbVie Position

AMF Tjanstepension held 30,909 shares of the drugmaker before the recent adjustment. The 21.9% reduction brought its total down to 24,119 shares.

Other Institutional Activity in AbbVie

Other major funds also adjusted their positions in the healthcare giant recently. Vest Financial grew its holdings by 43,631 shares, ending with 224,688 shares worth about $58.78 million. Pictet North America Advisors took a new position by buying 2,747 shares valued at about $718,588. Sumitomo Mitsui DS Asset Management Company reduced its stake by 32,919 shares to hold 291,632 shares worth about $76.29 million. AlphaStar Capital Management grew its holdings by 2,299 shares, finishing with 19,380 shares valued at about $5.07 million. Meanwhile, Y-Intercept exited its position entirely by selling 74,248 shares.

AbbVie Inc. Stock Down 0.2%

AbbVie shares recently traded around $284.80 as of October 22, 2026, closing at $284.94 on the day of the filing. The stock sits 49.3% above its 52-week low of $190.75 and 2.3% below its 52-week high of $291.40. It trades 8.5% above its 50-day moving average of $262.45 and 21.7% above its 200-day moving average of $233.95.

Recent Earnings

AbbVie reported trailing twelve-month revenue of $64.39 billion alongside earnings of $3.54 per share.

Dividend

The company pays an annual dividend of $6.92 per share.

Insider Buying and Selling at AbbVie Inc.

Company insiders executed several stock sales earlier in the year. General Counsel Perry C. Siatis sold 22,381 shares on February 25, 2026, at an average price of $230.00 for a total of $5,147,630. Siatis later sold 18,668 shares on March 2, 2026, valued at $4,375,549. Officer David Ryan Purdue sold 5,230 shares on March 4, 2026, at $233.56 per share for a total value of $1,221,519. Officer Nicholas Donoghoe sold 32,710 shares on August 14, 2026, at $250.00 per share for a total of $8,177,500.

Analysts Set New Price Targets

Wall Street firms updated their outlooks on the healthcare company ahead of its next financial report. On October 8, 2026, JP Morgan maintained an overweight rating and raised its price target from $285.00 to $300.00. UBS maintained a neutral rating on October 9, lifting its target from $260.00 to $275.00. Guggenheim reiterated a buy rating on October 9 with a $288.00 target. RBC Capital reiterated an outperform rating on October 13 with a $280.00 target. Barclays maintained an overweight rating on October 21 and raised its target from $300.00 to $325.00. Across the broader analyst community, the stock carries a consensus buy recommendation and a mean price target of $282.61.

About AbbVie

AbbVie Inc. is a research-focused biopharmaceutical company headquartered in North Chicago, Illinois. The firm develops and markets advanced therapies for complex conditions, including immunology treatments like Skyrizi and Rinvoq, oncology drugs such as Imbruvica and Venclexta, and therapies for various forms of cancer and lymphoma.

Bottom Line

Investors are keeping an eye on AbbVie as the company prepares to release its next earnings report on October 30, 2026. Institutional filings will continue to show how large holders adjust their portfolios following the upcoming results.